Rohto Pharmaceutical Co Ltd
TSE:4527

Watchlist Manager
Rohto Pharmaceutical Co Ltd Logo
Rohto Pharmaceutical Co Ltd
TSE:4527
Watchlist
Price: 2 371.5 JPY -0.71% Market Closed
Market Cap: ¥560.1B

Rohto Pharmaceutical Co Ltd
Other Equity

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Rohto Pharmaceutical Co Ltd
Other Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Equity CAGR 3Y CAGR 5Y CAGR 10Y
Rohto Pharmaceutical Co Ltd
TSE:4527
Other Equity
¥26.3B
CAGR 3-Years
22%
CAGR 5-Years
N/A
CAGR 10-Years
24%
Shiseido Co Ltd
TSE:4911
Other Equity
¥151.7B
CAGR 3-Years
27%
CAGR 5-Years
77%
CAGR 10-Years
25%
Kao Corp
TSE:4452
Other Equity
¥150.5B
CAGR 3-Years
58%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Kose Corp
TSE:4922
Other Equity
¥33.3B
CAGR 3-Years
27%
CAGR 5-Years
N/A
CAGR 10-Years
14%
F
Fancl Corp
TSE:4921
Other Equity
¥132m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
28%
Kobayashi Pharmaceutical Co Ltd
TSE:4967
Other Equity
¥13.7B
CAGR 3-Years
57%
CAGR 5-Years
N/A
CAGR 10-Years
26%
No Stocks Found

Rohto Pharmaceutical Co Ltd
Glance View

Market Cap
560.1B JPY
Industry
Consumer products

Rohto Pharmaceutical Co Ltd., a company deeply rooted in the legacy of Japanese innovation, traces its beginnings to the late 19th century. Initially specializing in over-the-counter (OTC) medicines, it has adeptly expanded its reach to include skincare and healthcare products. The company’s journey from its inception was marked by a relentless pursuit of addressing the evolving needs of its consumer base, leveraging its expertise in pharmaceuticals and chemistry to create products that cater to health and wellness. Rohto's commitment to research and development has enabled it to pioneer unique formulations, effectively blending traditional practices with modern scientific advances. This strategy has allowed Rohto to establish a strong foothold not only in Japan but also in international markets, appealing to a broad demographic. The core of Rohto's business lies in its ability to commercialize its innovative solutions across various channels. The company generates revenue primarily through the sale of its diversified product lines, which include eye drops, dermatological creams, and other personal care products. Rohto’s strategic acquisitions and partnerships have also played a critical role in its growth, enabling it to expand its market presence and adapt to global health trends. The ability to anticipate and respond to consumer needs allows Rohto to maintain a robust product pipeline, ensuring consistent sales performance. Through its global distribution networks and focused marketing efforts, Rohto capitalizes on its brand reputation for quality and reliability, ensuring a steady stream of profits.

Intrinsic Value
2 162.98 JPY
Overvaluation 9%
Intrinsic Value
Price ¥2 371.5

See Also

What is Rohto Pharmaceutical Co Ltd's Other Equity?
Other Equity
26.3B JPY

Based on the financial report for Dec 31, 2025, Rohto Pharmaceutical Co Ltd's Other Equity amounts to 26.3B JPY.

What is Rohto Pharmaceutical Co Ltd's Other Equity growth rate?
Other Equity CAGR 10Y
24%

Over the last year, the Other Equity growth was 26%. The average annual Other Equity growth rates for Rohto Pharmaceutical Co Ltd have been 22% over the past three years , and 24% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett